Reset filter
Nyckelord
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
    1. 7.1. Anestesi
    1. 7.2. Dermatologi
    1. 7.3. HNO
    1. 7.4. Geriatrik
    1. 7.5. Gynekologi och obstetrik
    1. 7.6. Invärtes medicin
      1. Hematologi
      1. Infektionssjukdomar
      1. Kardiologi och angiologi
      1. Pneumologi
      1. Gastroenterologi
      1. Nefrologi
      1. Endokrinologi och ämnesomsättning
      1. Reumatologi
    1. 7.7. Neurologi
    1. 7.8. Oftalmologi
    1. 7.9. Palliativ medicin
    1. 7.10. Patologi och rättsmedicin
    1. 7.11. Pediatrik
    1. 7.12. Psykiatri och psykosomatik
    1. 7.13. Radiologi
    1. 7.14. Kirurgi
      1. Allmänkirurgi och bukkirurgi
      1. Neurokirurgi
      1. Plastikkirurgi
      1. Hjärt- och thoraxkirurgi
      1. Akutkirurgi och ortopedi
      1. Kärlkirurgi
    1. 7.15. Urologi
    1. 7.16. Odontologi samt mun-, käk och ansiktskirurgi
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

932 Sökresultat.
Relevans Bedömning Nya först Gamla först

Venous access Registry Oncology Thromboses UK Essen - Venous access

- 2016-12-01 - 1 Formulär, 1 Item-grupp, 12 Dataelement, 1 Språk
Item-grupp: Venous access
Study part: Venous access Registry for oncologic patients with thromboses. The aim of the study was to determine the incidence of thrombosis in oncology patients. A register study of University Clinic Essen (UK Essen), permission granted by Claudia Ose from the Center for Clinical Studies Essen (Zentrums für Klinische Studien Essen, ZKSE).

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 03

- 2018-10-22 - 1 Formulär, 2 Item-grupper, 5 Dataelement, 1 Språk
Item-grupper: Follow-Up, Patient Discharge
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

dbGaP phs000289 NHGRI Genome-Wide Association Study of Venous Thromboembolism (GWAS of VTE) - pht001883.v1.p1

- 2022-10-12 - 5 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: pht001883
Principal Investigator: John A. Heit, MD, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA MeSH: Venous Thrombosis,Pulmonary Embolism,Deep Vein Thrombosis,Thrombophlebitis https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000289 *Overview:* *Our overall long-term goal is to determine risk factors for the complex (multifactorial) disease, venous thromboembolism (*VTE*), that will allow physicians to stratify individual patient risk and target VTE prophylaxis to those who would benefit most.* In this genome-wide association case-control study (1300 cases and 1300 controls) we hope to identify susceptibility variants for VTE. Mutations within genes encoding for important components of the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways are risk factors for VTE. We hypothesize that other genes within these four pathways or within other pathways also are VTE disease-susceptibility genes. Therefore, we performed a genome wide association (GWA) screen and analysis using the Illumina 660W platform to identify SNPs within 1,300 clinic-based, non-cancer VTE cases primarily from Minnesota and the upper Midwest USA, and 1300 clinic-based, unrelated controls frequency-matched on patient age, gender, myocardial infarction/stroke status and state of residence. This is a subset of a slightly larger candidate gene study using 1500 case-control pairs to identify haplotype-tagging SNPs (*ht*-SNPs) in a large set of candidate genes (n~750) within the anticoagulant, procoagulant, fibrinolytic, and innate immunity pathways. *Study Populations.* **Cases*.* VTE cases were consecutive Mayo Clinic outpatients with objectively-diagnosed deep vein thrombosis (DVT) and/or pulmonary embolism (PE) residing in the upper Midwest and referred by Mayo Clinic physician to the Mayo Clinic Special Coagulation Laboratory for clinical diagnostic testing to evaluate for an acquired or inherited thrombophilia, or to the Mayo Clinic Thrombophilia Center. Any person contacted to be a control but discovered to have had a VTE was evaluated for inclusion as a case. Cases were primarily residents from Minnesota, Wisconsin, Iowa, Michigan, Illinois, North or South Dakota, Nebraska, Kansas, Missouri and Indiana. A DVT or PE was categorized as objectively diagnosed when (a) confirmed by venography or pulmonary angiography, or pathology examination of thrombus removed at surgery, or (b) if at least one non-invasive test (compression duplex ultrasonography, lung scan, computed tomography scan, magnetic resonance imaging) was positive. A VTE was defined as:- Proximal leg deep vein thrombosis (DVT), which includes the common iliac, internal iliac, external iliac, common femoral, superficial [now termed "femoral"] femoral, deep femoral [sometimes referred to as "profunda" femoral] and/or popliteal veins. (Note: greater and lesser saphenous veins, or other superficial or perforator veins, were not included as proximal or distal leg DVT). - Distal leg DVT (or "isolated calf DVT"), which includes the anterior tibial, posterior tibial and/or peroneal veins. (Note: gastrocnemius, soleal and/or sural [e.g., "deep muscular veins" of the calf] vein thrombosis was not included as distal leg DVT). - Arm DVT, which includes the axillary, subclavian and/or innominate (brachiocephalic) veins. (Note: jugular [internal or external], cephalic and brachial vein thrombosis was not included in "arm DVT"). - Hepatic, portal, splenic, superior or inferior mesenteric, and/or renal vein thrombosis. (Note: ovarian, testicular, peri-prostatic and/or pelvic vein thrombosis was not included). - Cerebral vein thrombosis (includes cerebral or dural sinus or vein, saggital sinus or vein, and/or transverse sinus or vein thrombosis). - Inferior vena cava (IVC) thrombosis - Superior vena cava (SVC) thrombosis - Pulmonary embolism Patients with VTE related to active cancer, antiphospholipid syndrome, inflammatory bowel disease, vasculitis, a rheumatoid or other autoimmune disorder, a vascular anomaly (e.g., Klippel-Trénaunay syndrome, etc.), heparin-induced thrombocytopenia, or a mechanical cause for DVT (e.g., arm DVT or SVC thrombosis related to a central venous catheter or transvenous pacemaker, portal and/or splenic vein thrombosis related to liver cirrhosis, IVC thrombosis related to retroperitoneal fibrosis, etc.), with hemodialysis arteriovenous fistula thrombosis, or with prior liver or bone marrow transplantation were excluded. **Controls*.* A Mayo Clinic outpatient control group was prospectively recruited for this study. Controls were frequency-matched on the age group (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, and 80+ years), sex, myocardial infarction/stroke status, and state of residence distribution of the cases. We selected clinic-based controls using a controls' database of persons undergoing general medical examinations in the Mayo Clinic Departments of General Internal Medicine or Primary Care Internal Medicine. Additionally persons undergoing evaluation at the Mayo Clinic Sports Medicine Center, and the Department of Family Medicine were screened for inclusion as controls. This study is part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org) funded by the trans-NIH Genes, Environment, and Health Initiative (GEI). The overarching goal is to identify novel genetic factors that contribute to venous thrombosis through large-scale genome-wide association studies of 1,300 clinic-based, VTE cases and 1300 clinic-based, unrelated controls. Genotyping was performed at the Johns Hopkins University Center for Inherited Disease Research (CIDR). Data cleaning and harmonization were done at the GEI-funded GENEVA Coordinating Center at the University of Washington.

pht001884.v1.p1

1 Item-grupp 6 Dataelement

pht001885.v1.p1

1 Item-grupp 4 Dataelement

Eligibility

1 Item-grupp 12 Dataelement

pht001886.v2.p1

1 Item-grupp 39 Dataelement

Eligibility Pulmonary Arterial Hypertension NCT02032836

- 2021-09-17 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb); ODM derived from: https://clinicaltrials.gov/show/NCT02032836

Eligibility Pulmonary Arterial Hypertension NCT01841762

- 2021-06-23 - 1 Formulär, 2 Item-grupper, 28 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
SYMPHONY: A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT; ODM derived from: https://clinicaltrials.gov/show/NCT01841762

Eligibility Pulmonary Arterial Hypertension NCT00554619

- 2018-09-21 - 1 Formulär, 2 Item-grupper, 10 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
A Study to Evaluate GSK1325760A - a Long-Term Extension Study; ODM derived from: https://clinicaltrials.gov/show/NCT00554619

Eligibility Pulmonary Arterial Hypertension NCT00617305

- 2021-09-27 - 1 Formulär, 1 Item-grupp, 17 Dataelement, 1 Språk
Item-grupp: Criteria
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1); ODM derived from: https://clinicaltrials.gov/show/NCT00617305

Eligibility Pulmonary Arterial Hypertension NCT02516722

- 2019-06-26 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
TReatment Of Pulmonary HYpertension 1 Study; ODM derived from: https://clinicaltrials.gov/show/NCT02516722

Eligibility Pulmonary Arterial Hypertension NCT01553721

- 2019-01-17 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH); ODM derived from: https://clinicaltrials.gov/show/NCT01553721

Eligibility Pulmonary Arterial Hypertension NCT00814645

- 2018-09-22 - 1 Formulär, 2 Item-grupper, 8 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers; ODM derived from: https://clinicaltrials.gov/show/NCT00814645

Eligibility Primary Arterial Hypertension NCT00942487

- 2017-06-09 - 1 Formulär, 2 Item-grupper, 20 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol; ODM derived from: https://clinicaltrials.gov/show/NCT00942487

Eligibility Pulmonary Arterial Hypertension NCT00423748

- 2016-12-05 - 1 Formulär, 2 Item-grupper, 15 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.; ODM derived from: https://clinicaltrials.gov/show/NCT00423748

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial